Core A - Biospecimen Processing.
Core A - Biospecimen Processing.
批准号:
10194396
负责人:
PETER WESTERVELT
金额:
$13.95万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-03 至 2023-06-30
关键词:
AccreditationAcute leukemiaBone MarrowBone Marrow CellsCancer CenterCatalogsCharacteristicsClinicalClinical DataCollaborationsCollectionCommunitiesConsentDNA Sequence AlterationDiseaseEnrollmentEnsureEquipment and supply inventoriesFutureGenomicsGoalsHealth Insurance Portability and Accountability ActHematologic NeoplasmsInfrastructureInstitutionInstitutional Review BoardsInvestigationLinkMalignant NeoplasmsMissionNewly DiagnosedNucleic AcidsPathogenesisPatientsPreparationProcessPrognostic FactorProtocols documentationRelapseResearchResearch PersonnelResearch Project GrantsResourcesSerumServicesSkinSpecialized Program of Research ExcellenceSpecimenTimeTissue ProcurementsTissuesTranslational ResearchTreatment outcomeUniversitiesWashingtonanticancer researchbasebiobankchronic leukemiaclinical databasedata sharingepidemiologic dataexperienceinformatics toolleukemiaoperationpreservationprogramsprospectivesuccesstranslational cancer researchweb-based tool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
The goal of the Biospecimen Processing Core (BPC, Core A) is to provide high-quality, clinically annotated
biospecimens to all five research projects in this SPORE application as well as ongoing and future SPORE-
sponsored DRP and CEP projects, and to serve as an unparalleled biospecimen resource to the broader
cancer research community. The BPC will be responsible for the identification and enrollment of every patient
referred to the Siteman Cancer Center with newly diagnosed and relapsed hematologic malignancy (excluding
multiple myeloma). Biospecimens from these patients will be collected, processed, and stored by leveraging
the extensive infrastructure of the Siteman Cancer Center Tissue Procurement Core (TPC), a CAP-accredited
biorepository with over 15 years of experience in biospecimen banking. Clinical data will be collected
prospectively by integrating with and extending the mission of an existing Clinical Database Core (CDC),
previously established as part of the Genomics of AML (GAML) Program Project to serve as a platform for the
investigation of genetic mutations associated with the pathogenesis of MDS and AML. As such, Core A will
continue to supplement Cancer Center resources with focused expertise and effort to comprehensively collect,
annotate, quality review, and distribute biospecimens specifically for translational leukemia and leukemia-
related cancer research. Specific Aims include:
Specific Aim 1. To provide expertise in biobanking and clinical annotation to specifically support projects 1-
5 in this SPORE application.
Specific Aim 2. To provide an on-going, high quality, clinically annotated biospecimen resource of
hematological malignancy patient biospecimens for other translational research projects both within and
external to this SPORE program.
Specific Aim 3: To create a comprehensive and transparent plan to catalog collected biospecimens and
facilitate their distribution to the broader scientific community of hematologic malignancy investigators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.
-
批准号:10430084
-
项目类别:
-
资助金额:$16.57万
-
财政年份:2017
-
负责人:PETER WESTERVELT
-
依托单位:
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.
-
批准号:9385676
-
项目类别:
-
资助金额:$14.89万
-
财政年份:2017
-
负责人:PETER WESTERVELT
-
依托单位:
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.
-
批准号:10165782
-
项目类别:
-
资助金额:$16.96万
-
财政年份:2017
-
负责人:PETER WESTERVELT
-
依托单位:
A Phase II Study of Cytokine Induced Memory-like (CIML) Natural Killer (NK) Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.
-
批准号:9535449
-
项目类别:
-
资助金额:$17.05万
-
财政年份:2017
-
负责人:PETER WESTERVELT
-
依托单位:
Core A - Biospecimen Processing.
-
批准号:10439619
-
项目类别:
-
资助金额:$18.63万
-
财政年份:2013
-
负责人:PETER WESTERVELT
-
依托单位:
Core A - Biospecimen Processing.
-
批准号:10931074
-
项目类别:
-
资助金额:$11.83万
-
财政年份:2013
-
负责人:PETER WESTERVELT
-
依托单位:
Biospecimen Processing
-
批准号:8595804
-
项目类别:
-
资助金额:$20.94万
-
财政年份:2013
-
负责人:PETER WESTERVELT
-
依托单位:
Clinical Database
-
批准号:8375669
-
项目类别:
-
资助金额:$15.38万
-
财政年份:2012
-
负责人:PETER WESTERVELT
-
依托单位:
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization
-
批准号:8316237
-
项目类别:
-
资助金额:$15.73万
-
财政年份:2011
-
负责人:PETER WESTERVELT
-
依托单位:
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization
-
批准号:8495404
-
项目类别:
-
资助金额:$15.73万
-
财政年份:2011
-
负责人:PETER WESTERVELT
-
依托单位:
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization
-
批准号:8678988
-
项目类别:
-
资助金额:$15.73万
-
财政年份:2011
-
负责人:PETER WESTERVELT
-
依托单位:
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization
-
批准号:9069955
-
项目类别:
-
资助金额:$15.73万
-
财政年份:2011
-
负责人:PETER WESTERVELT
-
依托单位:
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell Mobilization
-
批准号:8174305
-
项目类别:
-
资助金额:$15.05万
-
财政年份:2011
-
负责人:PETER WESTERVELT
-
依托单位:
Clinical Database
-
批准号:7465880
-
项目类别:
-
资助金额:$14.19万
-
财政年份:2008
-
负责人:PETER WESTERVELT
-
依托单位:
Core A - Clinical Database.
-
批准号:10311213
-
项目类别:
-
资助金额:$33.21万
-
财政年份:2003
-
负责人:PETER WESTERVELT
-
依托单位:
Core A - Clinical Database.
-
批准号:10541179
-
项目类别:
-
资助金额:$35.03万
-
财政年份:2003
-
负责人:PETER WESTERVELT
-
依托单位:
DEVELOPMENTAL TARGETING--PML RARA EXPRESSION IN VIVO
-
批准号:6474959
-
项目类别:
-
资助金额:$9.94万
-
财政年份:1999
-
负责人:PETER WESTERVELT
-
依托单位:
DEVELOPMENTAL TARGETING--PML RARA EXPRESSION IN VIVO
-
批准号:2823311
-
项目类别:
-
资助金额:$11.2万
-
财政年份:1999
-
负责人:PETER WESTERVELT
-
依托单位:
DEVELOPMENTAL TARGETING--PML RARA EXPRESSION IN VIVO
-
批准号:6536544
-
项目类别:
-
资助金额:$13.43万
-
财政年份:1999
-
负责人:PETER WESTERVELT
-
依托单位:
DEVELOPMENTAL TARGETING--PML RARA EXPRESSION IN VIVO
-
批准号:6388519
-
项目类别:
-
资助金额:$1.78万
-
财政年份:1999
-
负责人:PETER WESTERVELT
-
依托单位:
海外基金